Korea's BioLeaders To Invest $10 Million in Weizmann Institute Anti-Cancer Therapy
BioLeaders has agreed to commit $10 million towards a company being spun off of Yeda Research and Development, Weizmann’s technology transfer arm
Adi Pick | 15:08 21.03.2019
Yongin, South Korea-headquartered biomedical company Bioleaders Corp. is looking at Israeli research institute The Weizmann Institute of Science for anti-cancer technology. BioLeaders has agreed to commit $10 million towards a company being spun off of Yeda Research and Development Co. Ltd., Weizmann’s technology transfer arm, the institute announced Tuesday. For daily updates, subscribe to our newsletter by clicking here. The spinoff, which will be jointly held by Yeda and BioLeaders, will develop a drug based on research from the institute’s molecular cell biology department.
This article has been updated to include the 2018 financial information for BioLeaders.
Hello. Is it possible to update/correct a few numbers in the article? Founded in 2000, BioLeaders is listed on the Korea Exchange and reported revenues of "KRW 7.6 billion ($6.7 million) in 2017." Should be updated to "KRW 86 billion (USD 76 million) in 2018." You can check the latest numbers on the KOSDAQ exchange website or on Bloomberg. https://www.bloomberg.com/quote/142760:KS